A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

Cancer

Volumn 117, Issue 20, 2011, Pages 4732-4739

  Kirkwood, John M ^a   Gonzalez, Rene ^b   Reintgen, Douglas ^c,i   Clingan, Philip R ^d   McWilliams, Robert R ^e   De Alwis, Dinesh P ^f   Zimmermann, Annamaria ^f   Brown, Michael P ^g   Ilaria Jr , Robert L ^f   Millward, Michael J ^h  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Lakeland Regional Cancer Center   (United States)

^d Southern Medical Day Care   (Australia)

^e MAYO CLINIC   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

chemotherapy; LY573636; melanoma; phase 2; tasisulam

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACARBAZINE; FOTEMUSTINE; PACLITAXEL; SORAFENIB; TASISULAM; TEMOZOLOMIDE; VINBLASTINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BLEEDING; CONSTIPATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; INJECTION SITE EXTRAVASATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BODY WEIGHT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SULFONAMIDES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80053906313     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26068     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, CA Cancer J Clin. 2002; 55: 74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin. 2009; 59: 225-249.
3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158-166. (Pubitemid 30036349)
4. Bajetta E, Del Vecchio, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002; 29: 427-445. (Pubitemid 35178282)
5. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24: 4738-4745. (Pubitemid 46630937)
6. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95: 581-586. (Pubitemid 44325897)
7. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009; 27: 2823-2830.
8. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. Proc Am Soc Clin Oncol. 2010; 28 (suppl): 7s. Abstract 8511.
9. Corbett TH, Valeriote FA, Polin L, et al. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In:, Valeriote FA, Corbett TH, Baker LH, eds. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Norwell, MA: Kluwer; 1990: 35-87.
10. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989; 81: 1088-1092. (Pubitemid 19175145)
11. Haritunians T, Gueller S, O'Kelly J, Ilaria R, Koeffler HP,. Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep. 2008; 20: 1237-1242.
12. Ilaria RL Jr, Simon GR, Sovak M, et al. Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 18S. Abstract 2515.
13. Janmahasatian S, Duffull SB, Ash S, Ward LC, Gyrne NH, Green B,. Quantification of lean bodyweight. Clin Pharmacokinet. 2005; 44: 1051-1065. (Pubitemid 41356391)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
15. Beal SL, Sheiner LB,. NONMEM Users Guides. Hanover, MD: GloboMax, Inc.; 1989-2006.
16. Kaplan EL, Meier P,. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
17. Sterling K,. The turnover rate of serum albumin in man as measured by I131-tagged albumin. J Clin Invest. 1951; 30: 1228-1237.
18. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032) [abstract]. Ann Oncol. 2008; 19 (suppl 8). Abstract LBA8.
19. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004; 22: 1118-1125. (Pubitemid 41095046)
20. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
21. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527-534. (Pubitemid 351264344)